Tuesday, November 15, 2011

Fitzsimons Redevelopment Authority Rolls Out 1st Phase of Strategic Refocus With Appointment of Four Key Leaders in Bioscience Industry to Its Board

In a strategic effort to refocus and strengthen its organization, the Fitzsimons Redevelopment Authority (FRA) has completed a regimen of planning to make adjustments in the direction, roles, responsibilities and allocation of resources going forward. The announcement is made by Denise Brown, FRA Interim Executive Director, who says, "Our first tactic in refocus involves augmenting our board of directors with four of the area's most well-known and successful leaders in the bioscience industry to help build programs and services to attract bioscience companies to relocate to Colorado and keep growing Colorado-based bioscience companies here, adding to our employment base. Modifying the board accordingly was approved in a recent board action."

Joining the FRA Board are (pictured L-R above): Donald M. Elliman, Jr., Executive Director of the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology and current Director and former Chair of the Children's Hospital Colorado Board of Directors; William Freytag, PhD, former Chairman and CEO of Myogen, Inc.; James C. T. Linfield, Partner-in-Charge of the Colorado office of Cooley LLP; and David Perez, President and Chief Executive Officer of CaridianBCT, becoming TerumoBCT.

Brown continues, "We're very pleased to welcome our new board members. These leaders are actively involved the bioscience community - locally, nationally and internationally - and maintain those critical relationships with entrepreneurs, companies and research groups required to guide the FRA through its next phase of growth. This is the first time the FRA has had bioscience executives on its board."

Link to the PR Web Newswire

Link to the Pitch Engine Social Media Release

No comments:

Post a Comment